牛牛AI助理已提取核心訊息
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
森蒂生物科學公司首席財務官兼企業發展主管黛博拉·諾貝爾曼於2024年2月1日完成了股票收購。該交易涉及免費贈送10.1萬股普通股。交易完成後，諾貝爾曼在該公司的直接持股量增加到總共13.1萬股。該補助金是公司薪酬結構的一部分，反映了高管對公司未來的持續承諾。
森蒂生物科學公司首席財務官兼企業發展主管黛博拉·諾貝爾曼於2024年2月1日完成了股票收購。該交易涉及免費贈送10.1萬股普通股。交易完成後，諾貝爾曼在該公司的直接持股量增加到總共13.1萬股。該補助金是公司薪酬結構的一部分，反映了高管對公司未來的持續承諾。
有用
沒用
該公告為獨立文件：